Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Danaher to Acquire GE’s Biopharma Biz for $21.4B | Contract Pharma

What are you searching for?

Sign in
Breaking News

Danaher to Acquire GE’s Biopharma Biz for $21.4B

The GE Life Sciences unit will join Danaher’s Life Science as a stand-alone business

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Danaher Corp. has entered an agreement to acquire General Electric’s biopharmaceutical business in a transaction valued at $21.4 billion.
 
The GE Life Sciences unit will join Danaher’s Life Science as a stand-alone business. The GE biopharma unit is expected to generate appoximately $3.2 billion in revenue this year. The acquisition is expected to be complete by 4Q19.
 
“We are focused on completing the carve out of the biopharma business, which is 15 percent of the $20 billion healthcare segment – and focused on managing the remaining core business,” GE chairman and chief executive officer Larry Culp told CNBC’s Morgan Brennan.
 
Cowen Research said in a note to investors that this deal came at “a rich valuation that goes a long way towards GE’s debt reduction.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters